首页> 外文OA文献 >Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis
【2h】

Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis

机译:巴西达成多发性硬化症的共识:巴西神经病学和巴西委员会治疗与研究委员会多发性硬化症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.
机译:摘要在多发性硬化症(MS)中扩张的治疗尸体允许更有效和个性化的治疗,但疾病改性疗法(DMT)的选择和管理变得越来越复杂。在这方面,巴西治疗和研究中的多发性硬化和神经内部内科的神经内部科学部门的专家召集了这一巴西对MS的待遇,根据他们的理解,神经病学家应该能够根据每位患者的最佳证据和实践,根据每个患者更好地规定MS DMTS。我们在此方面提出了对待遇的待遇的实际建议,主要关注DMTS的选择和管理,以及审查支持MS中的治疗策略的科学理论。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号